Sort   by:  
 Page size 
UnknownSafety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
Not available
S-EPMC3837092 | biostudies-literature
UnknownPooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Not available
S-EPMC5089162 | biostudies-literature
UnknownBEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Not available
S-EPMC4669379 | biostudies-literature
UnknownCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Not available
S-EPMC4226803 | biostudies-literature
UnknownEvaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Not available
S-EPMC5070547 | biostudies-literature
UnknownImatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Not available
S-EPMC4878082 | biostudies-literature
UnknownManagement of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Not available
S-EPMC6481621 | biostudies-literature
UnknownEfficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
Not available
S-EPMC5559888 | biostudies-literature
UnknownProgrammed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Not available
S-EPMC5562434 | biostudies-literature
UnknownHuman BioMolecular Atlas Program (HuBMAP): 3D Human Reference Atlas construction and usage.
Not available
S-EPMC11978508 | biostudies-literature
Sort   by:  
 Page size